157 related articles for article (PubMed ID: 38063077)
1. Dihydroxyacetone phosphate accumulation leads to podocyte pyroptosis in diabetic kidney disease.
Zhang Z; Hu H; Luo Q; Yang K; Zou Z; Shi M; Liang W
J Cell Mol Med; 2024 Feb; 28(3):e18073. PubMed ID: 38063077
[TBL] [Abstract][Full Text] [Related]
2. PFKP Activation Ameliorates Foot Process Fusion in Podocytes in Diabetic Kidney Disease.
Zhang Z; Liang W; Luo Q; Hu H; Yang K; Hu J; Chen Z; Zhu J; Feng J; Zhu Z; Chi Q; Ding G
Front Endocrinol (Lausanne); 2021; 12():797025. PubMed ID: 35095764
[TBL] [Abstract][Full Text] [Related]
3. Astragaloside IV Attenuates High-Glucose-Induced Impairment in Diabetic Nephropathy by Increasing Klotho Expression via the NF-
He J; Cui J; Shi Y; Wang T; Xin J; Li Y; Shan X; Zhu Z; Gao Y
J Diabetes Res; 2023; 2023():7423661. PubMed ID: 37261217
[TBL] [Abstract][Full Text] [Related]
4. STING deletion alleviates podocyte injury through suppressing inflammation by targeting NLRP3 in diabetic kidney disease.
Yang X; Chen Z; Luo Z; Yang D; Hao Y; Hu J; Feng J; Zhu Z; Luo Q; Zhang Z; Liang W; Ding G
Cell Signal; 2023 Sep; 109():110777. PubMed ID: 37329999
[TBL] [Abstract][Full Text] [Related]
5. Compromised glycolysis contributes to foot process fusion of podocytes in diabetic kidney disease: Role of ornithine catabolism.
Luo Q; Liang W; Zhang Z; Zhu Z; Chen Z; Hu J; Yang K; Chi Q; Ding G
Metabolism; 2022 Sep; 134():155245. PubMed ID: 35780908
[TBL] [Abstract][Full Text] [Related]
6. Complement factor B in high glucose-induced podocyte injury and diabetic kidney disease.
Lu Q; Hou Q; Cao K; Sun X; Liang Y; Gu M; Xue X; Zhao AZ; Dai C
JCI Insight; 2021 Oct; 6(19):. PubMed ID: 34622800
[TBL] [Abstract][Full Text] [Related]
7. Rutaecarpine protects podocytes in diabetic kidney disease by targeting VEGFR2/NLRP3-mediated pyroptosis.
Hu X; Wang J; Jiang L; Liu X; Ge Q; Wang Q; Qi X; Wu Y
Int Immunopharmacol; 2024 Mar; 130():111790. PubMed ID: 38447417
[TBL] [Abstract][Full Text] [Related]
8. ManNAc protects against podocyte pyroptosis via inhibiting mitochondrial damage and ROS/NLRP3 signaling pathway in diabetic kidney injury model.
Gao Y; Ma Y; Xie D; Jiang H
Int Immunopharmacol; 2022 Jun; 107():108711. PubMed ID: 35338958
[TBL] [Abstract][Full Text] [Related]
9. Astragaloside IV Inhibited Podocyte Pyroptosis in Diabetic Kidney Disease by Regulating SIRT6/HIF-1α Axis.
Zhang M; Liu W; Liu Y; Zhang Z; Hu Y; Sun D; Li S; Fang J
DNA Cell Biol; 2023 Oct; 42(10):594-607. PubMed ID: 37751175
[TBL] [Abstract][Full Text] [Related]
10. Fucoidan Alleviates Renal Fibrosis in Diabetic Kidney Disease
Wang MZ; Wang J; Cao DW; Tu Y; Liu BH; Yuan CC; Li H; Fang QJ; Chen JX; Fu Y; Wan BY; Wan ZY; Wan YG; Wu GW
Front Pharmacol; 2022; 13():790937. PubMed ID: 35370636
[No Abstract] [Full Text] [Related]
11. Inhibition of NLRP3 inflammasome ameliorates podocyte damage by suppressing lipid accumulation in diabetic nephropathy.
Wu M; Yang Z; Zhang C; Shi Y; Han W; Song S; Mu L; Du C; Shi Y
Metabolism; 2021 May; 118():154748. PubMed ID: 33675822
[TBL] [Abstract][Full Text] [Related]
12. MiR-21-5p in macrophage-derived extracellular vesicles affects podocyte pyroptosis in diabetic nephropathy by regulating A20.
Ding X; Jing N; Shen A; Guo F; Song Y; Pan M; Ma X; Zhao L; Zhang H; Wu L; Qin G; Zhao Y
J Endocrinol Invest; 2021 Jun; 44(6):1175-1184. PubMed ID: 32930981
[TBL] [Abstract][Full Text] [Related]
13. Pyruvate kinase M2 activation may protect against the progression of diabetic glomerular pathology and mitochondrial dysfunction.
Qi W; Keenan HA; Li Q; Ishikado A; Kannt A; Sadowski T; Yorek MA; Wu IH; Lockhart S; Coppey LJ; Pfenninger A; Liew CW; Qiang G; Burkart AM; Hastings S; Pober D; Cahill C; Niewczas MA; Israelsen WJ; Tinsley L; Stillman IE; Amenta PS; Feener EP; Vander Heiden MG; Stanton RC; King GL
Nat Med; 2017 Jun; 23(6):753-762. PubMed ID: 28436957
[TBL] [Abstract][Full Text] [Related]
14. Total Flavones of
Liu BH; Tu Y; Ni GX; Yan J; Yue L; Li ZL; Wu JJ; Cao YT; Wan ZY; Sun W; Wan YG
Front Pharmacol; 2021; 12():667644. PubMed ID: 34335245
[No Abstract] [Full Text] [Related]
15. Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy.
Susztak K; Raff AC; Schiffer M; Böttinger EP
Diabetes; 2006 Jan; 55(1):225-33. PubMed ID: 16380497
[TBL] [Abstract][Full Text] [Related]
16. Modified Hu-lu-ba-wan protects diabetic glomerular podocytes via promoting PKM2-mediated mitochondrial dynamic homeostasis.
Gong M; Guo Y; Dong H; Wu F; He Q; Gong J; Lu F
Phytomedicine; 2024 Jan; 123():155247. PubMed ID: 38128393
[TBL] [Abstract][Full Text] [Related]
17. Triptolide protects against podocyte injury in diabetic nephropathy by activating the Nrf2/HO-1 pathway and inhibiting the NLRP3 inflammasome pathway.
Lv C; Cheng T; Zhang B; Sun K; Lu K
Ren Fail; 2023 Dec; 45(1):2165103. PubMed ID: 36938748
[No Abstract] [Full Text] [Related]
18. Angiotensin II induces podocyte metabolic reprogramming from glycolysis to glycerol-3-phosphate biosynthesis.
Luo Z; Chen Z; Zhu Z; Hao Y; Feng J; Luo Q; Zhang Z; Yang X; Hu J; Liang W; Ding G
Cell Signal; 2022 Nov; 99():110443. PubMed ID: 35988808
[TBL] [Abstract][Full Text] [Related]
19. Solasonine alleviates high glucose-induced podocyte injury through increasing Nrf2-medicated inhibition of NLRP3 activation.
Zhang Q; Hu Y; Hu JE; Zhang M
Drug Dev Res; 2022 Nov; 83(7):1697-1706. PubMed ID: 36048966
[TBL] [Abstract][Full Text] [Related]
20. TRIM29 promotes podocyte pyroptosis in diabetic nephropathy through the NF-kB/NLRP3 inflammasome pathway.
Xu X; Qin Z; Zhang C; Mi X; Zhang C; Zhou F; Wang J; Zhang L; Hua F
Cell Biol Int; 2023 Jun; 47(6):1126-1135. PubMed ID: 36841942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
